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UD MEDICAL ETHICIST ALARMED BY BIO-TECH COMPANY'S REPORT 
THAT IT HAS CREATED FIRST HUMAN EMBRYOS BY CLONING 
DAYTON, Ohio- A Massachusetts company's announcement last week that it had 
created the first human embryos by cloning "demonstrates the violence that is done to ordinary 
language to sanitize these practices in order to 'sell' them," says a University of Dayton medical 
ethicist. 
"No longer is Advance Cell Technology referring to the clones as embryos. They're called 
activated eggs or cellular life," says Therese Lysaught, an assistant professor of religious studies 
at UD. "This is a deliberate attempt to manipulate public opinion. It is the use of language to 
obscure and deceive rather than communicate. It's propaganda- and that in itself is morally 
troubling." 
Equally disheartening is the company's "commodification of human life and of treating 
human beings as products," adds Lysaught, author of several professional papers on the 
subject, including "Holy Grail or Pandora's Box: Evaluating Human Embryonic Stem Cell 
Research" (The World and I magazine, Sept.-Oct. 1999). "This is a flagrant use of reproductive 
science and technology for the sole purpose of creating a sort of product- stem cells that 
match an individual's genetic makeup." 
The small bio-tech company has admitted the embryos died before any reached eight 
cells, which most cloning experts consider a failed experiment. Advance Cell Technology said it 
was not trying to create a human being but wanted to offer a method that would involve 
combining human eggs and a person's own cells to create embryos that would provide stem 
cells. The cells could then be used as replacement tissue in diseases such as diabetes and 
Parkinson's. 
The company's scientists used a standard technique that involves taking the genetic 
material out of an unfertilized egg and inserting in its place the DNA of an adult cell. The egg, in 
theory, then uses the genes from the adult cell to guide its development, turning into an embryo 
that is an exact copy of the donor of the adult cell. 
Lysaught also is concerned- as are other ethicists, scientists, public officials and many 
other Americans- by the company's disregard for public concern about this technology. 
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"It shows a complete lack of regard for the process of public moral conversation," she 
says, "for working together to try to understand the moral dimensions of our actions, our 
technologies, what it means to reproduce, what it means to be human." 
Lysaught, who teaches bioethics at UD and has served on the Recombinant DNA 
Advisory Committee of the National Institutes of Health, also is alarmed by what she calls a 
problem of the "therapeutic shift." The company has tried to justify this step on a therapeutic 
basis (i.e., replacement tissue could be an exact genetic match so a patient wouldn't need anti-
rejection drugs ), but "once the technologies are developed, there is nothing to stop anyone from 
using them for any purpose whatsoever, especially one that provides serious financial profits." 
Lysaught says the company's claims are dubious. 
"Researchers like those at Advance Cell Technologies argue that therapeutic cloning is 
necessary, that there is a risk of tissues developed from human embryonic stem cells being 
rejected by transplant recipients because they won't match and that tissues developed from 
clones of oneself wouldn't be rejected," Lysaught says. "However, one of the arguments 
justifying human embryonic stem cell research is that embryonic tissues, because they are 
undifferentiated, wouldn't be rejected by transplant recipients. That has been one of their Holy 
Grail characteristics. 
"So which is it?" she asks. "Contradictory arguments are put forward as new aspects of 
these technologies are developed. Of course, the obvious way to solve this problem is to work 
with adult stem cells, which continuing research is proving to be a real alternative." 
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For media interviews, contact Therese Lysaught at (937} 293-4734 or via e-mail at 
therese.lysaught@notes.udayton.edu. Her article "Holy Grail or Pandora's Box: Evaluating 
Human Embryonic Stem Cell Research" can be found at 
http: I I www.worldandi.com/ public/ 1999 I november I stemcell.shtml. 
